07:00 , Mar 16, 2015 |  BioCentury  |  Finance

Aura finds the right mix

Aura Biosciences Inc. has been developing its viral nanoparticle technology without the backing of institutional investors since 2009. New VC investors told BioCentury that Aura's work over the past 12-24 months to find the right...
02:27 , Mar 6, 2015 |  BC Extra  |  Financial News

Aura Biosciences raises $21M series B

Aura Biosciences Inc. (Cambridge, Mass.) raised $21 million in a series B round led by Advent Life Sciences. New investors Chiesi Ventures, Ysios Capital and Alexandria Venture Investments also participated, as did existing investors Li-Cor...
07:00 , Sep 8, 2014 |  BioCentury  |  Finance

Chiesi expands rare disease universe

Chiesi expands rare disease universe Chiesi Farmaceutici S.p.A. launched a strategic venture fund focused on rare and Orphan diseases - where the Italian pharma has been busily expanding - with an eye to building a...
08:00 , Feb 15, 2010 |  BioCentury  |  Finance

Anthera's test

The road show by cardiovascular and autoimmune play Anthera Pharmaceuticals Inc. will test the IPO market's appetite for companies with mid-stage product candidates. With Phase IIb data in hand for its lead candidate and $3.8...
08:00 , Dec 21, 2009 |  BioCentury  |  Finance

Ebb & Flow

The 2004 merger of Fujisawa Pharmaceutical Co. Ltd. and Yamanouchi Pharmaceutical Co. Ltd. to form Astellas Pharma Inc . (Tokyo:4503) has led to big payoffs in the last two weeks for Calixa Therapeutics Inc. and...
08:00 , Dec 18, 2006 |  BioCentury  |  Finance

Ebb & Flow

Affymax (AFFY) has checked off each of the three boxes for a blockbuster IPO: selling shares above the proposed price range, selling more shares than had been proposed, and trading up - way up -...
03:01 , Nov 30, 2005 |  BC Extra  |  Financial News

CeNeRx raises $18.5 million

CeNeRx ( Cary , N.C.) raised $18.5 million in a series A round led by Perseus-Soros. Other investors included L Capital Partners; A.M. Pappas & Associates; and Wistar Morris. CeNeRx is developing reversible inhibitors of...
07:00 , Sep 19, 2005 |  BioCentury  |  Finance

Ebb & Flow

FDA's accidental posting of briefing documents for Celgene's Revlimid a day ahead of schedule gave alert investors an afternoon of arbitrage last Monday. Typically, the agency posts its clinical and statistical reviews of a compound...
07:00 , Aug 29, 2005 |  BioCentury  |  Finance

Ebb & Flow

Dov (DOVP) fell $2.98 (17%) to $14.99 on 5.2 million shares on Friday after suspending dosing in a Phase III trial of ocinaplon to treat generalized anxiety disorder. The suspension followed enzyme elevations in liver...
00:29 , Aug 24, 2005 |  BC Extra  |  Top Story

Cerexa raises $50 million

Cerexa (Alameda, Calif.) raised $50 million in a series B round co-led by Frazier Healthcare and New Leaf. Other investors included Domain; Canaan; OrbiMed; A.M. Pappas; Montreux; EGS; and CDIB BioScience. Frazier's Patrick Heron and...